APTN-101’s unique mechanism of action is designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of therapies across the blood-brain barrier and selectively targeting EGFRvIII+ glioma cells Phase 1 study being conducted in collaboration with Duke University CHARLOTTE, N.C., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN) (“Adaptin” or the “Company”), a biotechnology company focused on developing precision cancer therapies with impr ...